Anti-GD2 monoclonal antibody for high-risk neuroblastoma advances toward BLA submission following successful tech transfer from California to Bengaluru
Backed by funding from an NIHR Doctoral Award, the guidance is focused on spotting abdominal tumours
Acquisition provides Ligand with the royalty rights to QARZIBA, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A.
These moves are designed to strengthen the company’s medical and scientific focus and support its continued record growth through closer alignment of all aspects of strategy, sales, and delivery to delight customers
The product will be available in 500 mg/2.5 mL and 1 g/5 mL vials
Subscribe To Our Newsletter & Stay Updated
